M&A Deal Summary

Norgine Acquires Merus Labs International

On May 11, 2017, Norgine acquired life science company Merus Labs International for 342M USD

Acquisition Highlights
  • This is Norgine’s 3rd transaction in the Life Science sector.
  • This is Norgine’s largest (disclosed) transaction.
  • This is Norgine’s 1st transaction in Canada.
  • This is Norgine’s 1st transaction in Ontario.

M&A Deal Summary
Date 2017-05-11
Target Merus Labs International
Sector Life Science
Buyer(s) Norgine
Deal Type Add-on Acquisition
Deal Value 342M USD
Advisor(s) Rothschild Global Advisory (Financial)
Torys LLP (Legal)

Target

Merus Labs International

Toronto, Ontario, Canada
Merus Labs International, Inc. is a specialty pharmaceutical company focused on acquiring and optimizing legacy and growth products. The Company leverages its expertise and scalable platform across Europe, Canada and select other markets to deliver value.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Norgine

Amsterdam, Netherlands
Category Company
Founded 1906
Sector Life Science
DESCRIPTION

Norgine is an independent specialty pharmaceutical company. Norgine’s focus is the development and marketing of pharmaceutical products that address significant unmet clinical needs in therapeutic areas such as gastroenterology, hepatology, and critical and supportive care. Norgine was formed in 1906 and is based in Amsterdam, Netherlands.

DEAL STATS #
Overall 4 of 5
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 1 of 2
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2017) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-28 Norgine - Middle East & North Africa Operations & Product Right

Netherlands

Norgine - Middle East & North Africa Operations & Product Right comprises a business unit that manufactures and markets pharmaceutical products.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-24 Azanta A/S

Valby, Denmark

Azanta A/S is a privately-owned specialty pharma company primarily operating within oncology, women's health and addiction medicine. Azanta A/S currently markets (or makes available under special authorization) a portfolio of specialty pharmaceutical products, including Nimorazole a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy and Angusta® for labor induction.

Buy -
Mergr

Product

Company

Legal